Abstract
Infective endocarditis (IE) incidence remains high with considerable fatality rates; guidelines for prophylaxis against IE are currently under review in some settings which highlights the importance of maintaining up-to-date epidemiological estimates about the most common microbial causes. The objective of this systematic review, following PRISMA guidelines, was to identify the most common microbial causes of IE in recent years. Medline was searched from January 1, 2003 to March 31, 2013 for all articles containing the term “infective endocarditis”. All relevant studies reporting diagnostic results were included. Special patient subpopulations were assessed separately. A total of 105 studies were included, from 36 countries, with available data on a total of 33,214 cases. Staphylococcus aureus was found to be the most common microorganism, being the most frequent in 54.3 % of studies (N = 57) (and in 55.4 % of studies using Duke’s criteria for diagnosis [N = 51]). Viridans group streptococci (VGS), coagulase-negative staphylococci (CoNS), Enterococcus spp and Streptococcus bovis were among the most common causes. S. aureus was the most common pathogen in almost all population subgroups; however, this was not the case in patients with implantable devices, prosthetic valves, or immunocompromised non-HIV, as well as in the sub-group from Asia, emphasizing that a global one-size-fits-all approach to the management of suspected IE is not appropriate. This review provides an evidence-based map of the most common causative agents of IE, highlighting S. aureus as the leading cause in the 21st century. The changing epidemiology of IE in some patient sub-groups in the last decade and the very high number of microbiologically undiagnosed cases (26.6 %) suggest the need to revisit IE prophylaxis and diagnostic strategies.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Infective endocarditis (IE) remains one of the most serious conditions in medicine in the 21st century [1, 2]. The introduction of antibiotics in its treatment has decreased the mortality rates of the disease; however, these can reach up to 20 % in hospital and can be even higher on 1-year follow up (up to 40 %) [3]. Fatality rates of IE remain high and 2.7% of patients suffer an unexpected sudden death at 6 months during or after treatment [4]. After the near eradication of rheumatic fever in the western world, infective endocarditis accounts for the vast majority of cases of endocarditis with an incidence ranging between 1.7 and 11.2 cases per 100.000 people/year [5]. Overall, the male to female ratio is estimated at around 2 but outcomes tend to be worse in women [6].
Incidence of IE is higher in elderly patients (reaching 14.5 cases per 100.000 person/years) [7] as well as among specific sub-populations such as injectable drug user(s) (IDUs) [8], where clinical characteristics of the disease also differ from the general population [9]. Diabetes mellitus, invasive techniques, haemodialysis [6, 10] and implantable cardiac devices [11] have caused a shift in the most commonly identified infective microorganisms in the past decades, significantly increasing the prevalence of staphylococcal infections [12] which generally had shown higher mortality rates when compared to streptococcal infections [6, 10, 13]. As a result, many studies have emphasized the need to better understand the mechanism of infection in cardiac devices and reinforce preventive measures of health-care associated staphylococcal bacteraemia in an effort to decrease IE incidence [11, 13].
Limited understanding of the disease pathogenesis and progression is reflected upon different guidelines for prophylaxis among countries in recent years [14]. Identifying the most common microbial agents in IE is of particular current interest, following publication of new research at the American Heart Association meeting in Chicago in November 2014 showing increase in the incidence of infective endocarditis and the subsequent launch of a review of the guidance on Prophylaxis for Infective Endocarditis by the National Institute for Health and Care Excellence, in the UK (http://www.nice.org.uk/news/press-and-media/nice-to-review-its-guidance-on-the-use-of-antibiotics-to-prevent-infective-endocarditis). As far as treatment is concerned, IE remains a therapeutic challenge to date primarily due to the changing epidemiology of the causative pathogens together with the lack of knowledge on the exact mechanism of the disease and the insufficiency of diagnostic and therapeutic methods [1]. Early surgical therapy is increasingly becoming more popular with studies showing superior outcomes when compared to conventional treatment [15].
In this context, the objective of this study was to systematically review the literature to identify and prioritize the most common microbial factors causing IE in recent years and provide insight on special subpopulations. The rationale was that if more definitive conclusions on microbial associations could be drawn, these could inform prevention and treatment strategies. In this context, the study followed an inclusive approach to record study results predicting the most common microbial diagnosis for the patients presenting with IE.
Methods
Search strategy
This systematic review adopted the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [16]. Eligible articles were identified by a systematic search of the Pubmed bibliographical database for studies published from January 1, 2003 to March 31, 2013 by three investigators (CV, NV, LP) working independently. All articles derived from a search with the term “infective endocarditis” were assessed. In addition, all references of eligible articles retrieved by the search were scanned. Whenever full text was not available or additional data information was required, an e-mail was sent to the corresponding authors.
Study eligibility was based on the following inclusion criteria: (1) observational studies in patients with infective endocarditis and explicit mention of the pathogens related to the disease, and (2) more than five patients with infective endocarditis reported in the article. Discrepancies were discussed until complete agreement was reached; an additional reviewer (AK) gave input where required to reach consensus. The selection process excluded: (1) reviews and secondary research, (2) case reports, (3) missing full text or key data, also excluding articles that only commented on a single pathogen, (4) overlapping populations, (5) irrelevant articles, i.e. articles not reporting on the etiologic agents of IE, and (6) articles published in languages other than English. In the interest of not excluding clinically important case series, no formal quality assessment of eligible articles was undertaken.
Data extraction
The following variables were extracted and tabulated for each eligible study: first author’s name, year of publication, study design, country of origin, study site, patients’ age (mean, standard deviation, median, and age range or interquartile range if available), reported use of Duke’s diagnostic criteria, number of cases, number of unidentified microbes, numbers of cases reported per microbe, as well as special patient subpopulations. Due to the anticipated high heterogeneity of the included studies and the inclusive character of the search strategy, the five most frequent microbes associated with each study were recorded (with polymicrobial and unspecified cases included when being numerically among the five main causes) and sensitivity analyses were performed. A purely descriptive approach was adopted (i.e. data expressed as non-weighted means whenever possible) concerning continuous variables. Microbial causes results and all descriptive variables were treated in numerical values of totals or means. No further statistical analysis was undertaken.
The species was recorded where available, otherwise the genus was used.
Results
Eligible articles
The initial search of the Pubmed database yielded 3,397 potentially relevant articles, 2,313 of which were excluded as irrelevant and 477 as not written in English. For the remaining 607 articles, the full-text was studied. Further exclusion reasons comprised 345 case reports, and 107 secondary research papers. Fourteen were excluded on account of overlapping populations (by majority relating to the International Collaboration on Endocarditis Prospective Cohort Study), results from 23 studies could not be included because they only described one pathogen, while for 13 studies, though requested through repeat correspondence, data could not be retrieved, in part, because there was no response from the corresponding authors. Four authors provided additional data on their studies [17–20].
Eventually, 105 studies were included in this review (Fig. 1) availing data for a total of 33,214 cases of infective endocarditis. Although the mean age of patients was not available in all studies, virtually all age groups were represented, with age ranging from 6 days to 100 years. However, paediatric patients were under-represented compared to adults. Ninety-two studies (87.6 %) used the Duke’s criteria or modified Duke’s criteria for case selection.
As shown in the Appendix, the majority of included studies (92.4 %, N = 97) used a cohort design (prospective: 30 / retrospective: 67), and only five were cross-sectional (4.8 %) and three case–control (2.9 %).
Most common microorganisms
Overall Staphylococcus aureus was found to be the most common microorganism causing infective endocarditis being isolated as one of the five most common microorganisms in 99 out of 105 studies (94.3 %), and being the most frequent in more than half of the studies (N = 57, 54.3 %), and second in a further third of the studies (N = 32, 30.5 %). Thirty-five of the above-mentioned 99 studies report data regarding MRSA strains; MRSA was isolated in the 4.5 % to 51.1 % of S. aureus infective endocarditis cases, while the median percentage was 28.1 Viridans group streptococci (VGS) were the second most commonly reported microorganisms, being the primary cause in over a fifth (21.9 %) of all studies (N = 23), and second in 24 studies (22.9 %) or third in 10. Coagulase-negative staphylococci (CoNS) were the most common not otherwise specified group recorded, isolated as the most frequent cause in 8.6 % of studies (N = 9), and reported as one of the five most common in 73.3 % (N = 77) of studies. Enterococcus spp was only rarely the most common microbe reported (N = 3), but it appeared consistently among the five most frequent in the majority of all studies (78.1 %, N = 82). Cases of Streptococcus bovis were also frequently reported, being the most common cause in three studies. The top decile of our studies (N = 11) comprised 18,065 cases. Of these studies, when using Duke's criteria, all but one had S. aureus as the most commonly diagnosed microbe. Only Day et al. [88] included a special sub-group: pediatric patients. This study contributes 61.6 % of the sample of this sub-group, substantially shifting the most common result towards S. aureus, as 4/7 studies report other microbes as most common. However, absolute sum of the results still points towards S. aureus, accounting for 45.4 % of all cases.
Table 1 summarises the most common pathogens per population category.
Special populations
Congenital heart defects
Five cohort studies (2 from Asia, 3 from Europe) examined 672 patients with congenital heart defects. S. aureus and VGS were almost equally identified among the most common pathogens in all five studies. Alpha hemolytic streptococci [21] and S. bovis [22] were also reported. All patients were included irrespective of the type of their congenital heart disease and whether they had undergone surgical correction or not. Patients were not stratified by age and effect of surgery.
Prosthetic valve
Three cohort studies reported exclusively 994 patients with prosthetic valve endocarditis. CoNS were the most commonly isolated microorganisms being the primary cause in one study and among the three most common microorganisms in the other two studies. S. aureus was the primary cause in one study and among the four most common pathogens in the other two studies. VGS were the main pathogen in the study authored by Lalani et al. [23]. Enterococcus spp. was the third most common microorganism in two out of three studies. Finally, Propionibacterium acnes appeared as the second most common causative agent in one study but not among the five most common microorganisms in the other two studies [24].
Paediatric patients
Seven retrospective cohort studies (3 from North America, 3 from Asia and 1 from Oceania) referred to 1,026 paediatric patients, their ages ranging from 3 days to 20 years. S. aureus was again found to be the most commonly isolated microorganism responsible for the disease (first in 3 studies and second in 4), followed by VGS (first in 3 studies and second in 2). CoNS ranked as the third most common pathogen in five out of seven studies. Two studies found Candida albicans to be the second and third most common pathogen, respectively [25, 26], while cases of Enterococcus spp were also reported.
Injectable drug user(s) (IDUs)
Four retrospective cohort studies (North America: 2, Asia: 1, Europe: 1) comprising a total of 580 cases examined the characteristics of IE among populations of IDUs. As expected, S. aureus was by far the most commonly isolated microorganism (first in 4 out of 5 studies). Three studies report MRSA strains, which were isolated in 11.4 %, 45.2 %, and 46.4 % of S. aureus infective endocarditis cases, respectively; VGS followed (second in 2 studies and third in 1 more study) and CoNS completed the triad of the most commonly isolated microorganisms (third in 2 studies). Enterococcus spp (fourth in 2 studies) and C. albicans (second and fifth in 2 studies respectively) were also reported.
Implantable heart devices
Six cohort studies examined 505 cases in patients with implantable heart devices. S. aureus and CoNS were isolated with equal frequency as the primary causative agents of the disease and were consistently found in the top five microorganisms causing IE in this special population. Enterococcus spp and Gram-negative bacteria, though not usually found among the three most common pathogens, comprised a big number of cases accounting as the fourth or fifth most common microbial agent isolated.
Fungal endocarditis
Sixteen studies (2,145 cases), 15 cohort and one cross-sectional, reported fungi as one of the five most frequent microbes causing infective endocarditis. These studies came primarily from Europe (N = 9) and Asia (N = 5), with one additional in the United States and one in Latin America. Fungi were reported as the third cause in one study, fourth in 2 studies and fifth in 2 studies. Candida species are reported in two studies as the fourth most common cause of endocarditis. C. albicans was the most frequently isolated fungus, as it is found in 6 % of studies (N = 7), thrice as the second cause, twice as the third and once as the fourth and fifth cause. Finally, Aspergillus fumigatus and Candida parapsilosis were isolated in only one study.
Using Duke’s criteria
A sensitivity analysis was performed among the 92 studies reporting use of the Duke’s criteria for diagnosis of IE and accounting for 22,081 cases of IE. The five most common pathogens were, in order of decreasing frequence, S. aureus, VGS, CoNS, Enterococcus spp and Streptococcus spp. S.aureus was found in a total of 5,546 cases and was the most common pathogen in 51 of these studies and second in 29. VGS were the second most common cause, found in a total of 2,694 cases, and it was the first cause in 24 studies and second in 22. CoNS followed, accounting for 1,765 cases of IE in total, being first in five studies and second in nine. Enterococcus spp was the fourth most common cause, isolated in 1,543 cases, and being the second common pathogen in fourth studies. Finally, Streptococcus spp was the fifth leading cause of IE, isolated in 1,145 patients in total, being the most common cause in seven studies and second in 6.
Results per continent
Forty-nine studies (46.7 %, N = 12,752 patients) originate from European countries, 29 from Asia (27.6 %, N = 12,105), 14 from North America (13.3 %, N = 1,918), four from Africa (3.8 %, N = 602), four from Oceania (3.8 %, N = 1,681 patients), two from South America (1.9 %, N = 452), and three were multi-continent (2.9 %, N = 3,704 patients). Table 2 summarizes the main microbial causes per continent.
Discussion
General population
As presented above, our study concluded that the five most common pathogens causing infective endocarditis in the 21st century are by order of frequency: S. aureus, viridans group streptococci (VGS), coagulase-negative staphylococci (CoNS), Enterococcus spp and S. bovis. S. aureus was the most common microorganism in over half of the studies included in our research.
Our results highlight the change in the epidemiology of the causative agents of IE throughout time, as they contrast studies from the 1990s reporting streptococcal infections outnumbering staphylococcal [27, 28], but are consistent with more recently published literature; Slipczuk et al. report a significant increase in S. aureus IE which may associate with increasing numbers of IDUs in North America [29]. Also, in a review published in 2006 streptococci and staphylococci were found to account for the vast majority of infective endocarditis cases [30]. Enterococci have been found to be the third leading cause of IE in other studies as well [13, 31]. On the other hand, quite surprisingly, a recent study carried out across 11 years in France identified S. bovis to be responsible for 149 of 847 cases (17.6 %) [4]. These changes in the pattern of the pathogens of IE can be attributed to several factors, such as modern cardiology invasive techniques, non-nosocomial health care acquisition, the growing importance of the central line associated blood stream infections (CLABSIs), the percentage of colonization by MRSA in cardiac surgery patients, the aging population and the rise of enterococci and S. bovis. Of note, frequency of identified microbes was not identified in the same pattern in Asia, strongly emphasizing that a global one-size-fits-all approach to the management of IE patients is not appropriate.
Special groups
This is the first study that has systematically assessed the cause of IE in several special patient groups of importance. Our study found that those with congenital heart defects did not differ significantly compared to the general IE population as far as causative microorganisms are concerned. S. aureus and VGS were the most commonly isolated microorganisms. Of interest, patients with bicuspid aortic valve were more prone to perivalvular abscess formation particularly when S. aureus was the causative microorganism of IE [22] and surgical intervention was required in a big number of cases—ranging between 26 and 72 %—to treat infective endocarditis [21, 22, 32, 33]. Taking into consideration that oral hygiene and dental prophylaxis seem to be of vital importance among these patients [32, 34] and that incidence of IE after reparative surgery has been increasing [34], revision of the current guidelines regarding patients with CHD is crucial. Similarly, among paediatric patients S. aureus was the most common pathogen, followed by VGS, CoNS, C. albicans and Enterococcus spp. This is in accordance with a recent study which reported increasing frequencies of S. aureus, CoNS and fungal IE among children [35]. A large proportion of the affected children had underlying heart disease as described in all the included studies. Of interest, Marom et al. noted that children with no predisposing factors exhibited a more aggressive form of the disease with S. aureus and S. pneumoniae being significantly more frequent among these patients [25]. On the other hand, patients with prosthetic valves were found positive for CoNS in the majority of cases, while S. aureus appeared second and VGS third. Of interest, CoNS infection conferred increased risk for perivalvular abscess development and heart failure compared to S. aureus and VGS IE [23]. Also, proportion of patients with early death was higher among patients with CoNS IE [24]. Thus, prompt attention should be given to antimicrobial prophylaxis against CoNS in patients with prosthetic valves. Our study identified that S. aureus was the most commonly reported cause of IE in IDUs and patients with implantable heart devices. Cases of CoNS and fungal endocarditis need to be explored in these patients. The extensive use of invasive methods and implantable devices in the past decades has changed the spectrum of microorganisms that tend to colonise the heart valves causing infective endocarditis. Cabell et al. described a 42 % increase in the use of implantable heart devices between 1990 and 1999, especially depicting the increased frequency of the use of permanent pacemaker, and leading to a 124 % increase in device infections and 50 % increase in infective endocarditis prevalence [11]. Thanavaro et al. suggested that the increased mortality and morbidity due to implantable cardiac devices infection can be partly attributed to the increased age of the patients and comorbidities [36]. Taking this evidence into account, revisions in guidelines regarding chemoprophylaxis after such procedures could be explored.
Limitations and strengths
Though inclusive, significant heterogeneity and a number of poorly designed studies among the included is the primary limitation of this review [37]. For example, a large cohort study from Thailand that reported non-fermentative Gram-negative rods as the leading cause is subject to various limitations, such as lack of use of the modified Duke’s criteria for patient selection and failure to identify a causative agent in 86.59 % of cases [38]. Also, the included studies used different ways to record the pathogens; some agents are reported by genuses, others by subgenuses and others by species making presentation of data inconsistent in terms of nomenclature. Notably, evidence of MRSA infection was only recorded in 35 out of 99 studies in which S. aureus was identified as one of the five most common microorganisms, and evidence of vancomycin-resistant S. epidermidis (VRSE) only in one study implicating enterococcal infections. A large number of studies routinely did not specify the species of fungi or Gram-negative microorganisms. Another possible limitation of this study is that the world population is represented disproportionally with the cases included in this review, as cases from Europe and Asia represent a 74.28 % of the total cases displayed. Also, excluding case reports and case series may lead to negative reporting bias for emerging pathogens and excluding non English literature may lead to selection bias.
Finally, in one in four of our included cases (8,835/33,214; 26.6 %) the causative agent was not identified. The above most likely reflect resource limited settings (or in a few cases poor laboratory techniques) and highlight the importance of the use of newer techniques, such as PCR, which may lead to an increase in the detection of the etiologic agents of infective endocarditis.
The review benefits from its strict methodology and the large number of studies and cases analysed. Sensitivity analyses were performed throughout. Notably, all five continents and various special subgroups are represented.
Conclusion
The present review is the largest epidemiological study regarding causative agents in IE including a collective cohort of 33,214 infective endocarditis cases. The results document the rapidly changing profile of IE etiology, especially among special sub-groups of patients, as well as the predominance of S. aureus as the leading cause for infective endocarditis in the 21st century. However, the most common agent differed among several special groups of patients (most notably implantable heart devices) as well as patients from Asia, showing the need to tailor patient prophylaxis and treatment. Also, our study showed that in an important percentage of IE cases the responsible agent remained unidentified, even in high-level reference laboratories; this stresses how newest techniques have the capacity to change the profile of IE diagnosis and prevention. The results further emphasize the need to revisit IE prophylaxis and management strategies, as well as improving the reporting of the causative agents in future studies.
References
Thuny F, Grisoli D, Collart F, Habib G, Raoult D (2012) Management of infective endocarditis: challenges and perspectives. Lancet 379:965–975
Habib G (2006) Management of infective endocarditis. Heart 92:124–130. doi:10.1136/hrt.2005.063719
Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS et al (2009) Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 169:463–473. doi:10.1001/archinternmed.2008.603
Thuny F, Hubert S, Tribouilloy C, Le Dolley Y, Casalta JP, Riberi A et al (2013) Sudden death in patients with infective endocarditis: findings from a large cohort study. Int J Cardiol 162:129–132
Htwe TH, Khardori NM (2012) Cardiac emergencies. Med Clin N Am 96:1149–1169. doi:10.1016/j.mcna.2012.09.003
Tornos P, Gonzalez-Alujas T, Thuny F, Habib G (2011) Infective endocarditis: the European viewpoint. Curr Probl Cardiol 36:175–222. doi:10.1016/j.cpcardiol.2011.03.004
Durante-Mangoni E, Bradley S, Selton-Suty C, Tripodi M-F, Barsic B, Bouza E et al (2008) Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med 168:2095–2103. doi:10.1001/archinte.168.19.2095
Sousa C, Botelho C, Rodrigues D, Azeredo J, Oliveira R (2012) Infective endocarditis in intravenous drug abusers: an update. Eur J Clin Microbiol Infect Dis 31:2905–2910. doi:10.1007/s10096-012-1675-x
Ortiz-Bautista C, López J, García-Granja PE, Sevilla T, Vilacosta I, Sarriá C et al (2015) Current profile of infective endocarditis in intravenous drug users: the prognostic relevance of the valves involved. Int J Cardiol 187:472–474. doi:10.1016/j.ijcard.2015.03.368
Cabell CH, Jollis JG, Peterson GE, Corey GR, Anderson DJ, Sexton DJ et al (2002) Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med 162:90–94
Cabell CH, Heidenreich PA, Chu VH, Moore CM, Stryjewski ME, Corey GR et al (2004) Increasing rates of cardiac device infections among medicare beneficiaries: 1990–1999. Am Heart J 147:582–586. doi:10.1016/j.ahj.2003.06.005
Nakagawa T, Wada H, Sakakura K, Yamada Y, Ishida K, Ibe T et al (2014) Clinical features of infective endocarditis: comparison between the 1990s and 2000s. J Cardiol 63:145–148. doi:10.1016/j.jjcc.2013.06.007
Fowler VG, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E et al (2005) Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293:3012–3021
Gregor P (2013) What’s new in the prevention of infective endocarditis? Cor Vasa 55:e520–e524. doi:10.1016/j.crvasa.2013.05.006
Kang D-H, Kim Y-J, Kim S-H, Sun BJ, Kim D-H, Yun S-C et al (2012) Early surgery versus conventional treatment for infective endocarditis. N Engl J Med 366:2466–2473
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 349:g7647–g7647. doi:10.1136/bmj.g7647
Chirillo F, Bacchion F, Pedrocco A, Scotton P, De Leo A, Rocco F et al (2010) Infective endocarditis in patients with diabetes mellitus. J Heart Valve Dis 19:312–320
Mokhles MM, Ciampichetti I, van Domburg R, Cheng JM, Bogers AJJC, Witsenburg M (2012) Infective endocarditis in a tertiary referral hospital: long-term follow up. J Heart Valve Dis 21:118–124
Yamane K, Hirose H, Bogar LJ, Cavarocchi NC, Diehl JT (2012) Surgical treatment of infective endocarditis in patients undergoing chronic hemodialysis. J Heart Valve Dis 21:774–782
Pazdernik M, Baddour LM, Pelouch R (2009) Infective endocarditis in the Czech Republic: eight years of experience at one of the country’s largest medical centers. J Heart Valve Dis 18:395–400
Niwa K (2005) Infective endocarditis in congenital heart disease: Japanese national collaboration study. Heart 91:795–800. doi:10.1136/hrt.2004.043323
Tribouilloy C, Rusinaru D, Sorel C, Thuny F, Casalta J-P, Riberi A et al (2010) Clinical characteristics and outcome of infective endocarditis in adults with bicuspid aortic valves: a multicentre observational study. Heart 96:1723–1729. doi:10.1136/hrt.2009.189050
Lalani T, Kanafani ZA, Chu VH, Moore L, Corey GR, Pappas P et al (2006) Prosthetic valve endocarditis due to coagulase-negative staphylococci: findings from the International Collaboration on Endocarditis Merged Database. Eur J Clin Microbiol Infect Dis 25:365–368. doi:10.1007/s10096-006-0141-z
Abramczuk E, Hryniewiecki T, Stepińska J (2007) Effects of pathogenic factors on prognosis in patients with prosthetic valve endocarditis. Kardiol Pol 65:115–122, discussion 123–4
Marom D, Ashkenazi S, Samra Z, Birk E (2013) Infective endocarditis in previously healthy children with structurally normal hearts. Pediatr Cardiol 34:1415–1421. doi:10.1007/s00246-013-0665-9
Lin Y-T, Hsieh K-S, Chen Y-S, Huang I-F, Cheng M-F (2013) Infective endocarditis in children without underlying heart disease. J Microbiol Immunol Infect 46:121–128. doi:10.1016/j.jmii.2012.05.001
Sandre RM, Shafran SD (1996) Infective endocarditis: review of 135 cases over 9 years. Clin Infect Dis Off Publ Infect Dis Soc Am 22:276–286
Levinson DC, Griffith GC, Pearson HE (1950) Increasing bacterial resistance to the antibiotics; a study of 46 cases of streptococcus endocarditis and 18 cases of staphylococcus endocarditis. Circulation 2:668–675
Slipczuk L, Codolosa JN, Davila CD, Romero-Corral A, Yun J, Pressman GS et al (2013) Infective endocarditis epidemiology over five decades: a systematic review. PLoS ONE 8:e82665. doi:10.1371/journal.pone.0082665
Bashore TM, Cabell C, Fowler V Jr (2006) Update on infective endocarditis. Curr Probl Cardiol 31:274–352. doi:10.1016/j.cpcardiol.2005.12.001
McDonald JR (2009) Acute infective endocarditis. Infect Dis Clin N Am 23:643–664. doi:10.1016/j.idc.2009.04.013
Di Filippo S (2006) Current patterns of infective endocarditis in congenital heart disease. Heart 92:1490–1495. doi:10.1136/hrt.2005.085332
Fortún J, Centella T, Martín-Dávila P, Lamas MJ, Pérez-Caballero C, Fernández-Pineda L et al (2013) Infective endocarditis in congenital heart disease: a frequent community-acquired complication. Infection 41:167–174. doi:10.1007/s15010-012-0326-6
Takeda S, Nakanishi T, Nakazawa M (2005) A 28-year trend of infective endocarditis associated with congenital heart diseases: a single institute experience. Pediatr Int 47:392–396
Rosenthal LB, Feja KN, Levasseur SM, Alba LR, Gersony W, Saiman L (2010) The changing epidemiology of pediatric endocarditis at a children’s hospital over seven decades. Pediatr Cardiol 31:813–820. doi:10.1007/s00246-010-9709-6
Thanavaro KL, Nixon JV (2014) Endocarditis 2014: an update. Heart Lung 43:334–337. doi:10.1016/j.hrtlng.2014.03.009
Dinnes J, Deeks J, Kirby J, Roderick P (2005) A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess Winch Engl 9:1–113, iii
Srifuengfung S, Yungyuen T, Komolpis P (2004) Bacterial isolation and antimicrobial susceptibilities in patients with infective endocarditis. Southeast Asian J Trop Med Public Health 35:897–901
Koegelenberg CFN (2003) Infective endocarditis in the Western Cape Province of South Africa: a three-year prospective study. QJM 96:217–225. doi:10.1093/qjmed/hcg028
Ako J, Ikari Y, Hatori M, Hara K, Ouchi Y (2003) Changing spectrum of infective endocarditis. Review of 194 episodes over 20 years. Circ J 67:3–7
Coward K, Tucker N, Darville T (2003) Infective endocarditis in Arkansan children from 1990 through 2002. Pediatr Infect Dis J 22:1048–1052
Valencia Ortega ME, Guinea J, Enrique A, Ortega G, Moreno V, Gonzalez Lahoz J (2003) Study of 42 cases of infective endocarditis in the HAART era in Spain. Clin Microbiol Infect 9:1073–1075
Nakatani S, Mitsutake K, Hozumi T, Yoshikawa J, Akiyama M, Yoshida K et al (2003) Current characteristics of infective endocarditis in Japan-an analysis of 848 cases in 2000 and 2001. Circ J 67:901–905
Di Salvo G (2003) Endocarditis in the elderly: clinical, echocardiographic, and prognostic features. Eur Heart J 24:1576–1583. doi:10.1016/S0195-668X(03)00309-9
Bishara J, Peled N, Samra Z, Sagie A, Leibovici L, Pitlik S (2004) Infective endocarditis in diabetic and non-diabetic patients. Scand J Infect Dis 36:795–798. doi:10.1080/00365540410025384
Rundström H, Kennergren C, Andersson R, Alestig K, Hogevik H (2004) Pacemaker endocarditis during 18 years in Göteborg. Scand J Infect Dis 36:674–679. doi:10.1080/00365540410022611
Spies C, Madison JR, Schatz IJ (2004) Infective endocarditis in patients with end-stage renal disease: clinical presentation and outcome. Arch Intern Med 164:71–75. doi:10.1001/archinte.164.1.71
Duval X, Suty CS, Alla F, Salvador-Mazenq M, Bernard Y, Weber M et al (2004) Endocarditis in patients with a permanent pacemaker: a 1-year epidemiological survey on infective endocarditis due to valvular and/or pacemaker infection. Clin Infect Dis 39:68–74
Loupa C, Mavroidi N, Boutsikakis I, Paniara O, Deligarou O, Manoli H et al (2004) Infective endocarditis in Greece: a changing profile. Epidemiological, microbiological and therapeutic data. Clin Microbiol Infect 10:556–561. doi:10.1111/j.1469-0691.2004.00884.x
Cecchi E, Forno D, Imazio M, Migliardi A, Gnavi R, Dal Conte I et al (2004) New trends in the epidemiological and clinical features of infective endocarditis: results of a multicenter prospective study. Ital Heart J Off J Ital Fed Cardiol 5:249–256
Tariq M, Alam M, Munir G, Khan MA, Smego RA (2004) Infective endocarditis: a five-year experience at a tertiary care hospital in Pakistan. Int J Infect Dis 8:163–170. doi:10.1016/j.ijid.2004.02.001
Barrau K, Boulamery A, Imbert G, Casalta J-P, Habib G, Messana T et al (2004) Causative organisms of infective endocarditis according to host status. Clin Microbiol Infect 10:302–308. doi:10.1111/j.1198-743X.2004.00776.x
Ben-Ami R, Giladi M, Carmeli Y, Orni-Wasserlauf R, Siegman-Igra Y (2004) Hospital-acquired infective endocarditis: should the definition be broadened? Clin Infect Dis 38:843–850
Liew WK, Tan TH, Wong KY (2004) Infective endocarditis in childhood: a seven-year experience. Singapore Med J 45:525–529
Chu J, Wilkins G, Williams M (2004) Review of 65 cases of infective endocarditis in Dunedin Public Hospital. N Z Med J 117:U1021
Mourvillier B, Trouillet J-L, Timsit J-F, Baudot J, Chastre J, Régnier B et al (2004) Infective endocarditis in the intensive care unit: clinical spectrum and prognostic factors in 228 consecutive patients. Intensive Care Med 30:2046–2052. doi:10.1007/s00134-004-2436-9
Tleyjeh IM, Steckelberg JM, Murad HS, Anavekar NS, Ghomrawi HM, Mirzoyev Z et al (2005) Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota. JAMA 293:3022–3028
Lewena S (2005) Infective endocarditis: experience of a paediatric emergency department. J Paediatr Child Health 41:269–272
Ruttmann E, Bonatti H, Legit C, Ulmer H, Stelzmueller I, Antretter H et al (2005) Severe endocarditis in transplant recipients - an epidemiologic study. Transpl Int 18:690–696. doi:10.1111/j.1432-2277.2005.00120.x
Garg N, Kandpal B, Garg N, Tewari S, Kapoor A, Goel P et al (2005) Characteristics of infective endocarditis in a developing country-clinical profile and outcome in 192 Indian patients, 1992–2001. Int J Cardiol 98:253–260. doi:10.1016/j.ijcard.2003.10.043
Benslimani A, Fenollar F, Lepidi H, Raoult D (2005) Bacterial zoonoses and infective endocarditis, Algeria. Emerg Infect Dis 11:216
Hsu C-N, Wang J-Y, Tseng C-D, Hwang J-J, Hsueh P-R, Liau C-S (2006) Clinical features and predictors for mortality in patients with infective endocarditis at a university hospital in Taiwan from 1995 to 2003. Epidemiol Infect 134:589. doi:10.1017/S0950268805005224
Martín-Dávila P, Fortún J, Navas E, Cobo J, Jiménez-Mena M, Moya JL et al (2005) Nosocomial endocarditis in a tertiary hospital: an increasing trend in native valve cases. Chest 128:772–779. doi:10.1378/chest.128.2.772
Tissières P, Jaeggi ET, Beghetti M, Gervaix A (2005) Increase of fungal endocarditis in children. Infection 33:267–272. doi:10.1007/s15010-005-4122-4
Thach Tran C, Kjeldsen K (2006) Endocarditis at a tertiary hospital: Reduced acute mortality but poor long term prognosis. Scand J Infect Dis 38:664–670. doi:10.1080/00365540600585180
Roca B, Marco JM (2007) Presentation and outcome of infective endocarditis in Spain: a retrospective study. Int J Infect Dis 11:198–203. doi:10.1016/j.ijid.2006.04.002
Walpot J, Blok W, van Zwienen J, Klazen C, Amsel B (2006) Incidence and complication rate of infective endocarditis in the Dutch region of Walcheren: a 3-year retrospective study. Acta Cardiol 61:175–181
Cicalini S, Puro V, Angeletti C, Chinello P, Macrì G, Petrosillo N (2006) Profile of infective endocarditis in a referral hospital over the last 24 years. J Infect 52:140–146. doi:10.1016/j.jinf.2005.02.025
Heiro M (2006) Infective endocarditis in a Finnish teaching hospital: a study on 326 episodes treated during 1980–2004. Heart 92:1457–1462. doi:10.1136/hrt.2005.084715
Ferreiros E, Nacinovich F, Casabé JH, Modenesi JC, Swieszkowski S, Cortes C et al (2006) Epidemiologic, clinical, and microbiologic profile of infective endocarditis in Argentina: a national survey. The Endocarditis Infecciosa en la República Argentina–2 (EIRA-2) Study. Am Heart J 151:545–552. doi:10.1016/j.ahj.2005.04.008
Hill EE, Herijgers P, Claus P, Vanderschueren S, Herregods M-C, Peetermans WE (2006) Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J 28:196–203. doi:10.1093/eurheartj/ehl427
Yiu K-H, Siu C-W, Lee KL-F, Fong Y-T, Chan H-W, Lee SW-L et al (2007) Emerging trends of community acquired infective endocarditis. Int J Cardiol 121:119–122. doi:10.1016/j.ijcard.2006.08.053
Gebo KA, Burkey MD, Lucas GM, Moore RD, Wilson LE (2006) Incidence of, risk factors for, clinical presentation, and 1-year outcomes of infective endocarditis in an urban HIV cohort. J Acquir Immune Defic Syndr 43:426–432
Abramczuk E, Hryniewiecki T, Stepińska J (2006) Influence of pathogenetic factors on prognosis in patients with native valve infective endocarditis. Kardiol Pol 64:675–681, discussion 682–3
De Rosa FG, Cicalini S, Canta F, Audagnotto S, Cecchi E, Di Perri G (2007) Infective endocarditis in intravenous drug users from Italy: the increasing importance in HIV-infected patients. Infection 35:154–160. doi:10.1007/s15010-007-5125-0
Nashmi A, Memish ZA (2007) Infective endocarditis at a tertiary care centre in Saudi Arabia: review of 47 cases over 10 years. East Mediterr Health J 13(1):64–71
Kamalakannan D, Pai RM, Johnson LB, Gardin JM, Saravolatz LD (2007) Epidemiology and clinical outcomes of infective endocarditis in hemodialysis patients. Ann Thorac Surg 83:2081–2086. doi:10.1016/j.athoracsur.2007.02.033
Giannitsioti E, Skiadas I, Antoniadou A, Tsiodras S, Kanavos K, Triantafyllidi H et al (2007) Nosocomial vs. community-acquired infective endocarditis in Greece: changing epidemiological profile and mortality risk. Clin Microbiol Infect 13:763–769. doi:10.1111/j.1469-0691.2007.01746.x
Wang A, Athan E, Pappas PA, Fowler VG, Olaison L, Paré C et al (2007) Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 297:1354–1361. doi:10.1001/jama.297.12.1354
Letaief A, Boughzala E, Kaabia N, Ernez S, Abid F, Chaabane TB et al (2007) Epidemiology of infective endocarditis in Tunisia: a 10-year multicenter retrospective study. Int J Infect Dis 11:430–433. doi:10.1016/j.ijid.2006.10.006
Krecki R, Drozdz J, Ibata G, Lipiec P, Ostrowski S, Kasprzak J et al (2007) Clinical profile, prognosis and treatment of patients with infective endocarditis—a 14-year follow-up study. Pol Arch Med Wewnętrznej 117:512–520
Lee C-H, Tsai W-C, Liu P-Y, Tsai L-M, Ho M-T, Chen J-H et al (2007) Epidemiologic features of infective endocarditis in Taiwanese adults involving native valves. Am J Cardiol 100:1282–1285. doi:10.1016/j.amjcard.2007.05.053
Hricak V, Liska B, Kovackova J, Mikusova J, Fischer V, Kovacik J et al (2007) Trends in risk factors and etiology of 606 cases of infective endocarditis over 23 years (1984–2006) in slovakia. J Chemother Florence Italy 19:198–202. doi:10.1179/joc.2007.19.2.198
Alshammary A, Hervas-Malo M, Robinson JL (2008) Pediatric infective endocarditis: has Staphylococcus aureus overtaken viridans group streptococci as the predominant etiological agent? Can J Infect Dis Med Microbiol 19:63
Siegman-igra Y, Koifman B, Porat R, Porat D, Giladi M (2008) Healthcare associated infective endocarditis: a distinct entity. Scand J Infect Dis 40:474–480. doi:10.1080/00365540701837357
Jain V, Yang M-H, Kovacicova-Lezcano G, Juhle LS, Bolger AF, Winston LG (2008) Infective endocarditis in an urban medical center: association of individual drugs with valvular involvement. J Infect 57:132–138. doi:10.1016/j.jinf.2008.05.008
Fernández-Hidalgo N, Almirante B, Tornos P, Pigrau C, Sambola A, Igual A et al (2008) Contemporary epidemiology and prognosis of health care–associated infective endocarditis. Clin Infect Dis 47:1287–1297. doi:10.1086/592576
Day MD, Gauvreau K, Shulman S, Newburger JW (2009) Characteristics of children hospitalized with infective endocarditis. Circulation 119:865–870. doi:10.1161/CIRCULATIONAHA.108.798751
Chao P-J, Hsu C-H, Liu Y-C, Sy C-L, Chen Y-S, Wann S-R et al (2009) Clinical and molecular epidemiology of infective endocarditis in intravenous drug users. J Chin Med Assoc JCMA 72:629–633. doi:10.1016/S1726-4901(09)70444-7
Wong CW, Porter G, Tisch J, Young C (2009) Outcome and prognostic factors on 57 cases of infective endocarditis in a single centre. N Z Med J 122:54–62
Al-Tawfiq JA, Sufi I (2009) Infective endocarditis at a hospital in Saudi Arabia: epidemiology, bacterial pathogens and outcome. Ann Saudi Med 29:433–436. doi:10.4103/0256-4947.57164
Nunes MCP, Gelape CL, Ferrari TCA (2010) Profile of infective endocarditis at a tertiary care center in Brazil during a seven-year period: prognostic factors and in-hospital outcome. Int J Infect Dis 14:e394–e398. doi:10.1016/j.ijid.2009.06.024
Tuğcu A, Yildirimtürk O, Baytaroğlu C, Kurtoğlu H, Köse O, Sener M et al (2009) Clinical spectrum, presentation, and risk factors for mortality in infective endocarditis: a review of 68 cases at a tertiary care center in Turkey. Turk Kardiyol Dern Ars 37:9–18
Le V, Gill S (2010) Serious complications after infective endocarditis. Dan Med Bull 57:A4192
Sy RW, Kritharides L (2010) Health care exposure and age in infective endocarditis: results of a contemporary population-based profile of 1536 patients in Australia. Eur Heart J 31:1890–1897. doi:10.1093/eurheartj/ehq110
Lomas JM, Martínez-Marcos FJ, Plata A, Ivanova R, Gálvez J, Ruiz J et al (2010) Healthcare-associated infective endocarditis: an undesirable effect of healthcare universalization. Clin Microbiol Infect 16:1683–1690. doi:10.1111/j.1469-0691.2010.03043.x
Saydain G, Singh J, Dalal B, Yoo W, Levine DP (2010) Outcome of patients with injection drug use–associated endocarditis admitted to an intensive care unit. J Crit Care 25:248–253. doi:10.1016/j.jcrc.2009.09.007
Siegman-Igra Y (2010) Infective endocarditis following gastrointestinal and genitourinary procedures: an argument in favour of prophylaxis. Scand J Infect Dis 42:208–214. doi:10.3109/00365540903443140
Khan NU, Farman MT, Sial JA, Achakzai AS, Saghir T, Ishaq M (2010) Changing trends of infective endocarditis. J Pak Med Assoc 60:24–27
Rostagno C, Rosso G, Puggelli F, Gelsomino S, Braconi L, Montesi GF et al (2010) Active infective endocarditis: clinical characteristics and factors related to hospital mortality. Cardiol J 17:566–573
Takayama Y, Okamoto R, Sunakawa K (2010) Definite infective endocarditis: clinical and microbiological features of 155 episodes in one Japanese university hospital. J Formos Med Assoc Taiwan Yi Zhi 109:788–799. doi:10.1016/S0929-6646(10)60124-6
Sucu M, Davutoğlu V, Özer O, Aksoy M (2010) Epidemiological, clinical and microbiological profile of infective endocarditis in a tertiary hospital in the South-East Anatolia Region. Congest Heart Fail 23:31–39
de Sa DDC, Tleyjeh IM, Anavekar NS, Schultz JC, Thomas JM, Lahr BD et al (2010) Epidemiological trends of infective endocarditis: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc 85:422–426. doi:10.4065/mcp.2009.0585
Demonchy E, Dellamonica P, Roger PM, Bernard E, Cua E, Pulcini C (2011) Audit of antibiotic therapy used in 66 cases of endocarditis. Médecine Mal Infect 41:602–607. doi:10.1016/j.medmal.2011.08.003
Wu K-S, Lee SS-J, Tsai H-C, Wann S-R, Chen J-K, Sy C-L et al (2011) Non-nosocomial healthcare-associated infective endocarditis in Taiwan: an underrecognized disease with poor outcome. BMC Infect Dis 11:221. doi:10.1186/1471-2334-11-221
Fedeli U, Schievano E, Buonfrate D, Pellizzer G, Spolaore P (2011) Increasing incidence and mortality of infective endocarditis: a population-based study through a record-linkage system. BMC Infect Dis 11:48
Math RS, Sharma G, Kothari SS, Kalaivani M, Saxena A, Kumar AS et al (2011) Prospective study of infective endocarditis from a developing country. Am Heart J 162:633–638. doi:10.1016/j.ahj.2011.07.014
Sonneville R, Mirabel M, Hajage D, Tubach F, Vignon P, Perez P et al (2011) Neurologic complications and outcomes of infective endocarditis in critically ill patients: The ENDOcardite en REAnimation prospective multicenter study. Crit Care Med 39:1474–1481
Rodriguez Y, Greenspon AJ, Sohail MR, Carrillo RG (2012) Cardiac device-related endocarditis complicated by spinal abscess: device-related endocarditis and spinal abscess. Pacing Clin Electrophysiol 35:269–274. doi:10.1111/j.1540-8159.2011.03288.x
Montasser D, Bahadi A, Zajjari Y, Asserraji M, Alayoude A, Moujoud O et al (2011) Infective endocarditis in chronic hemodialysis patients: experience from Morocco. Saudi J Kidney Dis Transpl 22:160
Chen S-J, Chao T-F, Lin Y-J, Lo L-W, Hu Y-F, Tuan T-C et al (2012) Cool seasons are related to poor prognosis in patients with infective endocarditis. Int J Biometeorol 56:973–981. doi:10.1007/s00484-011-0507-5
Olmos C, Vilacosta I, Fernandez C, Lopez J, Sarria C, Ferrera C et al (2013) Contemporary epidemiology and prognosis of septic shock in infective endocarditis. Eur Heart J 34:1999–2006. doi:10.1093/eurheartj/ehs336
Fernández-Hidalgo N, Almirante B, Tornos P, González-Alujas MT, Planes AM, Galiñanes M et al (2012) Immediate and long-term outcome of left-sided infective endocarditis. A 12-year prospective study from a contemporary cohort in a referral hospital. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 18:E522–E530. doi:10.1111/1469-0691.12033
Leone S, Ravasio V, Durante-Mangoni E, Crapis M, Carosi G, Scotton PG et al (2012) Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian Study on Endocarditis. Infection 40:527–535. doi:10.1007/s15010-012-0285-y
Casalta J-P, Thuny F, Fournier P-E, Lepidi H, Habib G, Grisoli D et al (2012) DNA persistence and relapses questions on the treatment strategies of enterococcus infections of prosthetic valves. PLoS ONE 7:e53335. doi:10.1371/journal.pone.0053335
Dohmen PM, Guleri A, Capone A, Utili R, Seaton RA, Gonzalez-Ramallo VJ et al (2013) Daptomycin for the treatment of infective endocarditis: results from a European registry. J Antimicrob Chemother 68:936–942. doi:10.1093/jac/dks467
Deharo J-C, Quatre A, Mancini J, Khairy P, Le Dolley Y, Casalta J-P et al (2012) Long-term outcomes following infection of cardiac implantable electronic devices: a prospective matched cohort study. Heart 98:724–731. doi:10.1136/heartjnl-2012-301627
Ipek EG, Guray U, Demirkan B, Guray Y, Aksu T (2012) Infections of implantable cardiac rhythm devices: predisposing factors and outcome. Acta Cardiol 67:303–310
Whitaker J, Williams S, Arujuna A, Rinaldi CA, Chambers J, Klein JL (2012) Cardiac implantable electronic device-related endocarditis: a 12-year single-centre experience. Scand J Infect Dis 44:922–926. doi:10.3109/00365548.2012.701015
Roig IL, Darouiche RO, Musher DM, Trautner BW (2012) Device-related infective endocarditis, with special consideration of implanted intravascular and cardiac devices in a predominantly male population. Scand J Infect Dis 44:753–760. doi:10.3109/00365548.2012.678882
Begezsán II, Bejan C, Ghibu L, Dorobăt CM, Roşu F (2012) Infective endocarditis in non-HIV immunosuppressed patients. Rev Medico-Chir Soc Medici Ş̧i Nat Din Iaş̧i 116:687–691
Dzupova O, Machala L, Baloun R, Maly M, Benes J (2012) Incidence, predisposing factors, and aetiology of infective endocarditis in the Czech Republic. Scand J Infect Dis 44:250–255. doi:10.3109/00365548.2011.632643
Duval X, Delahaye F, Alla F, Tattevin P, Obadia J-F, Le Moing V et al (2012) Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications. J Am Coll Cardiol 59:1968–1976. doi:10.1016/j.jacc.2012.02.029
Ashrafi R, McKay E, Ebden L, Jones J, Davis GK, Burgess MI (2012) Endocarditis in a large district general hospital: a study of the microbiological spectrum between 2000 and 2011. Exp Clin Cardiol 17:175
Fayad G, Vincentelli A, Leroy G, Devos P, Amr G, Prat A et al (2014) Impact of antimicrobial therapy on prognosis of patients requiring valve surgery during active infective endocarditis. J Thorac Cardiovasc Surg 147:254–258. doi:10.1016/j.jtcvs.2012.10.019
Nakatani S, Mitsutake K, Ohara T, Kokubo Y, Yamamoto H, Hanai S et al (2013) Recent picture of infective endocarditis in Japan. Circ J 77:1558–1564. doi:10.1253/circj.CJ-12-1101
Acknowledgments
The authors are thankful to Drs F. Chirillo, M.M. Mokhles, M. Pazdernik and K. Yamane for providing original data or full texts related to their publications.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study received no funding.
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
No identifying information is included in this study.
Additional information
Christiana T. Vogkou and Nikolaos I. Vlachogiannis contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 491 kb)
Appendix
Appendix
All studies included in this review can be found in Table 3.
Rights and permissions
About this article
Cite this article
Vogkou, C.T., Vlachogiannis, N.I., Palaiodimos, L. et al. The causative agents in infective endocarditis: a systematic review comprising 33,214 cases. Eur J Clin Microbiol Infect Dis 35, 1227–1245 (2016). https://doi.org/10.1007/s10096-016-2660-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-016-2660-6